Frontiers in Behavioral Neuroscience
June 23, 2021
Alina Wilkowska, Łukasz P. Szałach, Wiesław Jerzy Cubała
32 citations
According to the WHO, major depressive disorder is the leading cause of disability worldwide, and it is a major contributor to the overall global burden of disease. The pathophysiology of this common and chronic disease is still not completely understood. The gut microbiome is an increasingly recognized environmental factor that can have a role in depression, acting through the...
Frontiers in Psychiatry
June 22, 2021
Sadhna Verma, James Donovan, Hari S. Tunuguntla et al.
Background: Depression, anxiety, and disordered sleep are some common symptoms associated with sub-optimal mental health. During the COVID-19 pandemic, mental health issues have grown increasingly more prevalent in the population. Due to social distancing and other limitations during the pandemic, there is a need for home-based, flexible interventions that can improve mental health. The Yoga of...
Health Psychology Research
June 22, 2021
Sahar Derakhshanian, Maxine Zhou, Alexander Rath et al.
21 citations
PURPOSE OF REVIEW: This is a comprehensive review of the literature regarding the use of ketamine as a treatment for treatment-resistant depression (TRD). It covers the epidemiology, risk factors, pathophysiology, and current treatment modalities regarding Major Depressive Disorder (MDD) and TRD. It provides background on the mechanism of action of ketamine, its history, current approved and...
Current Psychology
June 21, 2021
Haley McKeen, M. Hook, Purnaja Podduturi et al.
Adverse childhood experiences (ACEs) have been associated with a variety of negative physical and psychological health outcomes. The mechanisms by which this occurs and potential protective factors present in this relationship are understudied. Mindfulness is a cognitive resource that may protect individuals against symptoms of psychological distress. It has five core facets and encourages a...
World Journal of Psychiatry
June 19, 2021
Hewa Artin, S. Zisook, Dhakshin Ramanathan
Depression is a common mental disorder and one of the leading causes of disability around the world. Monoaminergic antidepressants often take weeks to months to work and are not effective for all patients. This has led to a search for a better understanding of the pathogenesis of depression as well as to the development of novel antidepressants. One such novel antidepressant is ketamine, which...
Di-san junyi daxue xuebao
June 18, 2021
LU Fang, XU Yuanyuan, YU Yongju et al.
Objective To investigate the level of emotional exhaustion and its relationship with depression and posttraumatic stress disorder symptoms in intensive care unit (ICU) nurses and explore the moderating effects of mindfulness. Methods From March, 2016 to April 2017, we conducted a survey of the levels of emotional exhaustion, mindfulness, depression and posttraumatic stress disorder among 500...
Journal of Sleep Research
June 16, 2021
Nelson B Rodrigues, Roger S McIntyre, Orly Lipsitz et al.
28 citations
Summary Sleep disturbances are commonly reported in patients with treatment‐resistant depression (TRD). Available data have shown that intravenous (IV) ketamine is an effective treatment for patients with TRD and growing data suggest ketamine may improve overall sleep architecture. In the present study, we evaluated whether changes in sleep symptoms mediated the anti‐depressive and/or...
Science Translational Medicine
June 9, 2021
Peter Nagele, Ben J Palanca, Britt M Gott et al.
Nitrous oxide at 50% inhaled concentration has been shown to improve depressive symptoms in patients with treatment-resistant major depression (TRMD). Whether a lower concentration of 25% nitrous oxide provides similar efficacy and persistence of antidepressant effects while reducing the risk of adverse side effects is unknown. In this phase 2 clinical trial (NCT03283670), 24 patients with...
European Neuropsychopharmacology
June 2, 2021
A. Feeney, Rebecca S. Hock, Marlene P. Freeman et al.
33 citations
This study aimed to assess the effect of a single infusion of intravenous (IV) ketamine on suicidal ideation in patients with treatment-resistant depression (TRD). Patients with TRD were randomized in a double-blind fashion to a single infusion of IV ketamine or IV midazolam placebo. Suicidal ideation was measured using the Montgomery-Asberg Depression Rating Scale (MADRS) suicide item at 3, 5,...
BJPsych Open
June 1, 2021
James McLoughlin, Paula Martin, Geraldine McCarthy et al.
Aims: Mindfulness-based therapies have been demonstrated to be effective in reducing anxiety, stress and depressive symptoms in adults. Depression is a chronic relapsing condition. Major depressive disorder is one of the most common causes of ill health and functional impairment. Our goal was to assess the real world clinical effectiveness of Mindfulness Based Cognitive Therapy (MBCT) for...
East Asian Archives of Psychiatry
June 1, 2021
Vivian Wy Shih, W. Chan, On Tai et al.
BACKGROUND Rumination and overgeneral autobiographical memory are dysfunctional cognitions commonly found in older adults with depression. The theoretical underpinnings of mindfulness-based cognitive therapy (MBCT) address the ruminative tendencies and the non-specific retrieval of autobiographical memories. This study aims to examine the efficacy and cognitive mechanisms of MBCT in older...
Frontiers in Psychology
June 1, 2021
Dongjiao An, Changwei Wei, Jing Wang et al.
46 citations
Background There is growing interest in glutamatergic agents as a treatment for depression, especially intranasal ketamine, which has become a hot topic in recent years. We aim to assess the efficacy and safety of intranasal ketamine in the treatment of major depressive disorder (MDD), especially treatment-resistant depression (TRD). Methods We searched Medline, EMBASE, and the Cochrane Library...
BJPsych Open
June 1, 2021
Amber Elyse Corrigan, Ella Burchill, Lucy Pelton et al.
1 citation
Aims Depression is the single largest contributor to global disability. However, effective treatments are currently lacking, resulting in a significant burden of treatment-resistant depression (TRD). Psilocybin, a serotonergic psychedelic, found as the active compound in 'magic mushrooms', has been proposed as a novel therapeutic avenue for TRD. We aimed to evaluate the future feasibility and...
Gadjah Mada Journal of Professional Psychology
May 31, 2021
Ainurizan Ridho Rahmatulloh, Sofia Retnowati
Suicide is a global epidemic phenomenon that is the third most common cause of death in the world. However, not many studies have focused on developing an intervention that specifically targets symptoms of suicidal ideation. Suicidal ideation is seen as part of a depressed condition. The purpose of this study was to validate a cognitive-based mindfulness program to reduce suicidal ideation in...
bioRxiv Preprint Server
May 30, 2021
Calvin K. Young, Kachina G. Kinley, Neil McNaughton
preprint
Depression is highly prevalent, increases suicide risk, and is now the leading cause of disability worldwide. Our ability to treat depression is hampered by the lack of understanding of its biological underpinnings and of the mode of action of effective treatments. We hypothesised that the scaffolding proteins in the medial frontal cortex play a major role in effective antidepressant action. We...
Frontiers in Psychiatry
May 28, 2021
V. B. Cavenaghi, Leandro Paulino da Costa, Acioly L T Lacerda et al.
41 citations
Background: Ketamine has been shown to produce a rapid and robust antidepressant effect. Though numerous routes of administration have been studied, subcutaneous (SC) has proven to be a convenient and cost-effective route making its use particularly relevant in developing countries. Here we provide a systematic review covering the use of SC racemic ketamine and esketamine in depression,...
The Journal of Alternative and Complementary Medicine
May 25, 2021
Laura Lozano Montes, Vandana Balakrishnan, S. Gopalakrishnan
Objective: We aimed to study the short-term effects of Integrated Amrita Meditation (IAM) technique in anxiety and depression states and to have a better understanding on the underlying physiological changes related to short-term and long-term IAM practice. Design: Short-term IAM practitioners (ST-IAM) and long-term IAM practitioners (LT-IAM) were compared to control groups of the same age and...
The British Journal of Psychiatry
May 25, 2021
Emily Ionson, Jayneel Limbachia, Soham Rej et al.
We, the Editors of BJPsych, have retracted the following article: Effects of Sahaj Samadhi meditation on heart rate variability and depressive symptoms in patients with late-life depression, Ionson, E., Limbachia, J., Rej, S., Puka, K., Newman, R. I., Wetmore, S., Burhan, A. M. and Vasudev, A, The British Journal of Psychiatry (2019), Cambridge University Press, 214(4), pp. 218–224. DOI:...
Neurobiology of Learning and Memory
May 25, 2021
Igor Magaraggia, Zilla Kuiperes, Rudy Schreiber
49 citations
The high symptomatic and biological heterogeneity of major depressive disorder (MDD) makes it very difficult to find broadly efficacious treatments that work against all symptoms. Concentrating on single core symptoms that are biologically well understood might consist of a more viable approach. The Research Domain Criteria (RDoC) framework is a trans-diagnostic dimensional approach that...
Research Square
May 20, 2021
Richard E. Daws, Christopher Timmerman, Bruna Giribaldi et al.
11 citations
preprint
Abstract Importance Psilocybin therapy shows antidepressant potential; our data link its antidepressant effects to decreased brain network modularity post-treatment. Objective To assess the sub-acute impact of psilocybin on brain activity in patients with depression. Design Pre vs post-treatment resting-state functional MRI (fMRI) was recorded in two trials: 1) Open-label treatment-resistant...